Assembly Biosciences, Inc. ASMB

– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it

LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.

IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.

LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.

MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 – – Cash runway projected into 2029, including first $75 million Gilead collaboration extension p